marketing is the key to poh growth, page-56

I ve no problem with a placement /raising to provide funds to enable a Phase2/3 TPM/oxycodone patch trial to be conducted. The co has a choice to do this or do a smaller deal earlier and have a partner fund these trials.....however we do have a possible 3 commercial deals which may generate substantial cash for the company this year. Novartis Animal Insulin, Derma acne drug and Psoriasis drug all have commercial deals in place pending collaborative trials meeting partners end points. In addition we have the real biggie in CSL and a possible licensing of Mastitis Management. Meanwhile POHs personal care line is now rolling with a full order book for first shipment of Body Shaper and apparent great sales success for Elixia via partnership with TVSN. So no...there is absolutely no certainty that POH will need another cap raising at all. It's a matter for the board to juggle which route may deliver the best outcome for POH for Oxy and what kind of up fronts these other commercial deals can deliver near term....if they are lucrative...there may well be sufficient spare cash to fund late stage trials for One or more of POHs lead drug candidates.....note no mention of 100 million plus earnings in this post....but you have to admit whichever side of the fence you stand...POH has a lot if irons in the fire, tech is virtually risk-free, money is under control and the future for POH seems very bright

KC